Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth 29-01-2025, 19:00

King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells 30-10-2023, 22:14